1. ¹Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA
2. ²Michael E DeBakey Veterans Affairs Medical Center, Houston, TX, USA
3. ³Department of Radiology, Baylor College of Medicine, Houston, TX, USA
4. ⁴Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA

Correspondence: Dr TC Thompson, Department of Genitourinary Medical Oncology, Unit 1374, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. E-mail: timthomp@mdanderson.org

Received 18 August 2008; Revised 13 November 2008; Accepted 13 November 2008; Published online 23 December 2008.

Abstract

We evaluated the potential use of intraoperative gelatin matrix hemostatic sealant (GMHS; FloSeal; Baxter Healthcare) embedded with macrophages (M) transduced with murine interleukin (IL)-12 recombinant adenoviral vector (G/M/AdmIL-12) for prevention of recurrence of prostate cancer following radical prostatectomy. Application of G/M/AdmIL-12 resulted in significant suppression of tumor growth and spontaneous lung metastases, a statistically significant survival advantage of the G/M/AdmIL-12-treated animals, more efficient trafficking of M to lymph nodes draining from the prostate and generation of systemic natural killer cell activity and tumor-specific cytolytic T lymphocyte responses compared to the controls in a preclinical mouse model of residual prostate cancer. Our data recommend this treatment as a novel adjuvant for prevention of local recurrence of prostate cancer following radical prostatectomy.